Developer docs
API playgroundTry for free, no card

Search company profiles

AudioCure Pharma

Full company profile

uuid00036sc

Namestring
AudioCure Pharma
Legal namestring
AudioCure Pharma GmbH
Websiteurl
audiocure.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

AudioCure Pharma GmbH is a privately held, clinical-stage pharmaceutical company headquartered in Berlin, Germany, developing drug treatments for hearing disorders with high unmet medical need. The company was founded by Prof. Hans Rommelspacher, a former head of Clinical Neurobiology at Charité University Berlin, and is led by CEO Dr. Reimar Schlingensiepen. Its lead asset AC102 is a novel betacarboline (fluorcarboline) small molecule designed to act on three pathological processes in the inner ear—protecting outer hair cells from cell death, enabling repair of inner hair cells and their synaptic connections to the auditory nerve, and reducing inflammation. AC102 is delivered via a proprietary gel formulation administered by intratympanic injection, optimizing local drug concentration while minimizing systemic exposure.

The company is running a multinational Phase 2 trial enrolling approximately 200 adult patients with sudden sensorineural hearing loss (SSNHL) at up to 45 European study centers across Austria, Czech Republic, Germany, Poland, Serbia and the Netherlands. AC102 has received orphan drug designation from both the EMA (January 2019) and the FDA (March 2021), positioning it as a potential first-in-class disease-modifying therapy for SSNHL and acute tinnitus—indications for which no approved drugs exist worldwide. Preclinical data published in PNAS (2024) demonstrated near-complete restoration of noise-induced hearing loss after a single dose in animal models, and Phase 1 results in 42 healthy volunteers confirmed safety and tolerability.

AudioCure's business model is pre-commercial pharmaceutical R&D: it currently generates no product revenue and relies on equity financing from strategic and institutional investors including MED-EL (Austria, implantable hearing devices), High-Tech Gründerfonds (HTGF, Germany), and most recently InfectoPharm (Germany, ENT specialty pharma), which led a new financing round in February 2025. Future revenue is expected from drug sales upon regulatory approval, supplemented by an exclusive licensing arrangement with MED-EL granted as part of the 2016 Series A. The company employs 1–10 staff and operates from a single Berlin office at Geneststraße 5.

Short descriptiontext

AudioCure Pharma is a Berlin-based, clinical-stage pharmaceutical company developing AC102, a novel betacarboline small molecule delivered intratympanically as a gel, for the treatment of sudden sensorineural hearing loss and acute tinnitus in adults.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBerlin, Germany
HQ citystring
Berlin
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
hearing loss therapeutics, otology pharmaceuticals, inner ear drug development, small molecule therapeutics, clinical stage biotechnology
Industry1 code
PRIMARYHLAKAMAC
Otology & Neurotology (Ear/Hearing/Balance)
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Hearing Loss Therapeutics (Otorhinolaryngology Pharmaceuticals)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical drug development and commercialization
TypeOne Time License
Description

AudioCure is a clinical-stage pharmaceutical R&D company developing AC102 for the treatment of sudden sensorineural hearing loss (SSNHL) and acute tinnitus. The company has not yet generated product revenue as AC102 is still in Phase 2 clinical trials. Future revenue would come from drug sales upon regulatory approval.

audiocure.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

AudioCure Pharma develops AC102, a novel betacarboline small-molecule drug candidate formulated as an intratympanic gel, for the treatment of sudden sensorineural hearing loss (SSNHL), acute tinnitus, and electrode insertion trauma during cochlear implantation. The compound acts on multiple pathological processes in the inner ear (outer hair cell protection, inner hair cell repair, synaptic restoration, and anti-inflammation) and is being advanced through multinational Phase 2 clinical trials in Europe.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • AC102 nearly completely restores noise-induced hearing loss in guinea pig models to almost pre-noise levels after single dose (PNAS 2024)
+2 more records
Product overview1 text field

AudioCure Pharma is a clinical-stage pharmaceutical company developing a portfolio of novel small molecule drug candidates for the treatment of hearing disorders. The company's primary product is AC102, a disease-modifying therapeutic candidate for acute hearing loss and acute tinnitus, administered via a specialized intratympanic gel formulation. Additional development programs target tinnitus treatment and preservation of residual hearing in cochlear implant patients.

Product and service2 records
1AC102
CategoryHearing loss therapeutics / Otorhinolaryngology pharmaceutical
Description

Novel betacarboline small-molecule drug candidate in clinical development for the treatment of sudden sensorineural hearing loss (SSNHL) and acute tinnitus. AC102 acts on three key pathological processes of inner-ear disease — protection of outer hair cells from cell death, repair of synaptic connections between inner hair cells and the auditory nerve, and reduction of inflammation — and is administered as a single intratympanic dose via a specialized gel formulation. It has orphan drug designations from both the EMA (January 2019) and FDA (March 2021) and is currently in a multinational Phase 2 clinical trial.

2AC102 for Electrode Insertion Trauma (EIT)
CategoryHearing implant adjunct therapy
Description

Application of the AC102 small molecule to the prevention of hearing loss caused by electrode insertion trauma during cochlear implantation. Developed in collaboration with MED-EL, which holds exclusive licensing rights to this indication. Preclinical studies are conducted with the Medical University of Vienna to assess AC102's ability to preserve residual hearing following cochlear implant surgery.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Phase 1 clinical trial conducted at Radboudumc in The Netherlands. Principal investigator Dr. Ronald Pennings led first-in-human study assessing safety and tolerability of AC102 after injection into the middle ear of healthy volunteers.

2University Hospital Erlangen
Strategic tierSecondaryTypeStrategic or Co-development Partner
Description

Joint research collaboration with Erlangen University Hospital and AudioCure on tinnitus research. Study published in International Journal of Molecular Sciences showing AC102 nearly completely reversed tinnitus in preclinical model after single dose while restoring damaged connections between auditory nerve and inner ear sensory cells.

audiocure.com
Strategic tierSecondaryTypeStrategic or Co-development Partner
Description

Collaboration with Dr. Julian Hellmann-Regen, Head of Clinical Neurobiology Laboratory, to further investigate molecular mode of action of AC102. Research focused on understanding how AC102 protects and restores inner ear cells.

4Medical University of Vienna (Allgemeines Krankenhaus)
Strategic tierSecondaryTypeStrategic or Co-development Partner
Description

Phase 1 study site and collaboration on electrode insertion trauma research. Dr. Michael Nieratschker presented preclinical results on AC102 for preservation of residual hearing following cochlear implantation, conducted with MED-EL and AudioCure.

audiocure.com
5Martin Luther University Halle-Wittenberg
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Prof. Dr. Stefan Plontke serves as Coordinating Investigator for Phase 2 clinical trial. Prof. Plontke is Director of the ENT Clinic at University Medicine Halle and leading expert on sudden hearing loss treatment.

audiocure.com
Strategic tierSecondaryTypeStrategic or Co-development Partner
Description

Earlier collaboration with Dr. Wernicke from Wildau and Dr. Enzensperger from University of Jena for in vitro screening and testing of AC102. Dr. Wernicke received Research Award 2013 for work on hearing loss treatment approaches through NeuroPro Alliance.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1Otonomy
TypeDirect peer
Description

Otonomy is a clinical-stage biopharmaceutical company developing therapies for ear disorders including SSNHL and Ménière's disease. It is the most directly comparable public peer, sharing AudioCure's focus on intratympanic drug delivery and otology indications.

TypeDirect peer
Description

Sensorion is a French clinical-stage biotech developing small-molecule and gene therapies for hearing loss disorders including SSNHL and ototoxicity. Direct competitor in the SSNHL space with Phase 2 assets and orphan designations.

TypeDirect peer
Description

Frequency Therapeutics developed regenerative small-molecule therapies for sensorineural hearing loss, advancing lead candidates through clinical trials. Direct peer in the pharmacological treatment of inner ear hearing loss with Phase 1/2 assets.

TypeDirect peer
Description

Decibel Therapeutics was a clinical-stage biotech developing therapeutics for hearing and balance disorders before acquisition by Regeneron in 2023. Direct comparable for a hearing-loss-focused biotech with gene therapy and small-molecule approaches.

TypeDirect peer
Description

Spiral Therapeutics is a clinical-stage company developing intratympanic therapies for inner ear disorders including hearing loss. Shares AudioCure's specialized drug delivery approach and otology focus.

TypeEmerging player
Description

Rinri Therapeutics is a UK-based emerging biotech developing regenerative cell therapies for sensorineural hearing loss. Comparable as a hearing-loss therapeutics innovator though operating in a different modality (cell therapy vs small molecule).

TypeEmerging player
Description

Audion Therapeutics is a Netherlands-based emerging biotech developing small-molecule therapeutics for hearing loss and inner ear regeneration. Directly comparable in therapeutic area with Phase 1 assets in hearing loss.

8Strekin AG
TypeEmerging player
Description

Strekin AG is a Swiss clinical-stage biotech focused on otology indications including SSNHL and hearing loss. Emerging peer operating in the same therapeutic space with small-molecule pipeline assets.

TypeBroad incumbent
Description

MED-EL is the global leader in cochlear implant systems and an existing AudioCure investor/partner developing electrode insertion trauma applications for AC102. Broader incumbent in hearing loss treatment with overlapping R&D on drug-device combination approaches.

TypeDirect peer
Description

Pipeline Therapeutics (formerly ProQR spin-out) is developing small-molecule therapies targeting inner ear disorders. Direct peer in hearing loss small-molecule development with comparable clinical-stage assets.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AudioCure Pharma

Hearing Loss Therapeutics (Otorhinolaryngology Pharmaceuticals)audiocure.com

AudioCure Pharma is a Berlin-based, clinical-stage pharmaceutical company developing AC102, a novel betacarboline small molecule delivered intratympanically as a gel, for the treatment of sudden sensorineural hearing loss and acute tinnitus in adults.

What AudioCure Pharma does

AudioCure Pharma GmbH is a privately held, clinical-stage pharmaceutical company headquartered in Berlin, Germany, developing drug treatments for hearing disorders with high unmet medical need. The company was founded by Prof. Hans Rommelspacher, a former head of Clinical Neurobiology at Charité University Berlin, and is led by CEO Dr. Reimar Schlingensiepen. Its lead asset AC102 is a novel betacarboline (fluorcarboline) small molecule designed to act on three pathological processes in the inner ear—protecting outer hair cells from cell death, enabling repair of inner hair cells and their synaptic connections to the auditory nerve, and reducing inflammation. AC102 is delivered via a proprietary gel formulation administered by intratympanic injection, optimizing local drug concentration while minimizing systemic exposure.

The company is running a multinational Phase 2 trial enrolling approximately 200 adult patients with sudden sensorineural hearing loss (SSNHL) at up to 45 European study centers across Austria, Czech Republic, Germany, Poland, Serbia and the Netherlands. AC102 has received orphan drug designation from both the EMA (January 2019) and the FDA (March 2021), positioning it as a potential first-in-class disease-modifying therapy for SSNHL and acute tinnitus—indications for which no approved drugs exist worldwide. Preclinical data published in PNAS (2024) demonstrated near-complete restoration of noise-induced hearing loss after a single dose in animal models, and Phase 1 results in 42 healthy volunteers confirmed safety and tolerability.

AudioCure's business model is pre-commercial pharmaceutical R&D: it currently generates no product revenue and relies on equity financing from strategic and institutional investors including MED-EL (Austria, implantable hearing devices), High-Tech Gründerfonds (HTGF, Germany), and most recently InfectoPharm (Germany, ENT specialty pharma), which led a new financing round in February 2025. Future revenue is expected from drug sales upon regulatory approval, supplemented by an exclusive licensing arrangement with MED-EL granted as part of the 2016 Series A. The company employs 1–10 staff and operates from a single Berlin office at Geneststraße 5.

AudioCure Pharma firmographics

Firmographics
Name
AudioCure Pharma
Legal name
AudioCure Pharma GmbH
Website
https://audiocure.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
11–50 employees
Short description
AudioCure Pharma is a Berlin-based, clinical-stage pharmaceutical company developing AC102, a novel betacarboline small molecule delivered intratympanically as a gel, for the treatment of sudden sensorineural hearing loss and acute tinnitus in adults.
Ownership category
akta.pro rank

AudioCure Pharma industry classification

Industry
Product category
Hearing Loss Therapeutics (Otorhinolaryngology Pharmaceuticals)
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAKAMAC
Otology & Neurotology (Ear/Hearing/Balance)

Keywords

  • Hearing loss therapeutics
  • Otology pharmaceuticals
  • Inner ear drug development
  • Small molecule therapeutics
  • Clinical stage biotechnology

Where AudioCure Pharma is headquartered

Location

Headquarters

HQ city
Berlin
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

AudioCure Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical drug development and commercialization: AudioCure is a clinical-stage pharmaceutical R&D company developing AC102 for the treatment of sudden sensorineural hearing loss (SSNHL) and acute tinnitus. The company has not yet generated product revenue as AC102 is still in Phase 2 clinical trials. Future revenue would come from drug sales upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

AudioCure Pharma product offering

Product offering

Core offering

AudioCure Pharma develops AC102, a novel betacarboline small-molecule drug candidate formulated as an intratympanic gel, for the treatment of sudden sensorineural hearing loss (SSNHL), acute tinnitus, and electrode insertion trauma during cochlear implantation. The compound acts on multiple pathological processes in the inner ear (outer hair cell protection, inner hair cell repair, synaptic restoration, and anti-inflammation) and is being advanced through multinational Phase 2 clinical trials in Europe.

Product overview

AudioCure Pharma is a clinical-stage pharmaceutical company developing a portfolio of novel small molecule drug candidates for the treatment of hearing disorders. The company's primary product is AC102, a disease-modifying therapeutic candidate for acute hearing loss and acute tinnitus, administered via a specialized intratympanic gel formulation. Additional development programs target tinnitus treatment and preservation of residual hearing in cochlear implant patients.

Differentiator

Problem solved

Functional benefit

Products and services

  • AC102 Novel betacarboline small-molecule drug candidate in clinical development for the treatment of sudden sensorineural hearing loss (SSNHL) and acute tinnitus. AC102 acts on three key pathological processes of inner-ear disease — protection of outer hair cells from cell death, repair of synaptic connections between inner hair cells and the auditory nerve, and reduction of inflammation — and is administered as a single intratympanic dose via a specialized gel formulation. It has orphan drug designations from both the EMA (January 2019) and FDA (March 2021) and is currently in a multinational Phase 2 clinical trial.
  • AC102 for Electrode Insertion Trauma (EIT) Application of the AC102 small molecule to the prevention of hearing loss caused by electrode insertion trauma during cochlear implantation. Developed in collaboration with MED-EL, which holds exclusive licensing rights to this indication. Preclinical studies are conducted with the Medical University of Vienna to assess AC102's ability to preserve residual hearing following cochlear implant surgery.

Quantifiable outcome

  • AC102 nearly completely restores noise-induced hearing loss in guinea pig models to almost pre-noise levels after single dose (PNAS 2024)
  • +2 more outcomes

Companies that use AudioCure Pharma

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles2 records

AudioCure Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

AudioCure Pharma partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and secondary.

  • Radboud University Medical Center (Radboudumc)coreStrategic or Co-development PartnerPhase 1 clinical trial conducted at Radboudumc in The Netherlands. Principal investigator Dr. Ronald Pennings led first-in-human study assessing safety and tolerability of AC102 after injection into the middle ear of healthy volunteers.
  • University Hospital ErlangensecondaryStrategic or Co-development PartnerJoint research collaboration with Erlangen University Hospital and AudioCure on tinnitus research. Study published in International Journal of Molecular Sciences showing AC102 nearly completely reversed tinnitus in preclinical model after single dose while restoring damaged connections between auditory nerve and inner ear sensory cells.
  • Charité Universitätsmedizin BerlinsecondaryStrategic or Co-development PartnerCollaboration with Dr. Julian Hellmann-Regen, Head of Clinical Neurobiology Laboratory, to further investigate molecular mode of action of AC102. Research focused on understanding how AC102 protects and restores inner ear cells.
  • Medical University of Vienna (Allgemeines Krankenhaus)secondaryStrategic or Co-development PartnerPhase 1 study site and collaboration on electrode insertion trauma research. Dr. Michael Nieratschker presented preclinical results on AC102 for preservation of residual hearing following cochlear implantation, conducted with MED-EL and AudioCure.
  • Martin Luther University Halle-WittenbergcoreStrategic or Co-development PartnerProf. Dr. Stefan Plontke serves as Coordinating Investigator for Phase 2 clinical trial. Prof. Plontke is Director of the ENT Clinic at University Medicine Halle and leading expert on sudden hearing loss treatment.
  • Technical University of Applied Sciences, WildausecondaryStrategic or Co-development PartnerEarlier collaboration with Dr. Wernicke from Wildau and Dr. Enzensperger from University of Jena for in vitro screening and testing of AC102. Dr. Wernicke received Research Award 2013 for work on hearing loss treatment approaches through NeuroPro Alliance.

Scale indicators6 records

Recent moves6 records

Expansion highlights4 records

AudioCure Pharma competitors and assessment

Company assessment

Direct peers

  • Otonomy: Otonomy is a clinical-stage biopharmaceutical company developing therapies for ear disorders including SSNHL and Ménière's disease. It is the most directly comparable public peer, sharing AudioCure's focus on intratympanic drug delivery and otology indications.
  • Sensorion: Sensorion is a French clinical-stage biotech developing small-molecule and gene therapies for hearing loss disorders including SSNHL and ototoxicity. Direct competitor in the SSNHL space with Phase 2 assets and orphan designations.
  • Frequency Therapeutics: Frequency Therapeutics developed regenerative small-molecule therapies for sensorineural hearing loss, advancing lead candidates through clinical trials. Direct peer in the pharmacological treatment of inner ear hearing loss with Phase 1/2 assets.
  • Decibel Therapeutics (Regeneron): Decibel Therapeutics was a clinical-stage biotech developing therapeutics for hearing and balance disorders before acquisition by Regeneron in 2023. Direct comparable for a hearing-loss-focused biotech with gene therapy and small-molecule approaches.
  • Spiral Therapeutics: Spiral Therapeutics is a clinical-stage company developing intratympanic therapies for inner ear disorders including hearing loss. Shares AudioCure's specialized drug delivery approach and otology focus.
  • Pipeline Therapeutics: Pipeline Therapeutics (formerly ProQR spin-out) is developing small-molecule therapies targeting inner ear disorders. Direct peer in hearing loss small-molecule development with comparable clinical-stage assets.

Emerging players

  • Rinri Therapeutics: Rinri Therapeutics is a UK-based emerging biotech developing regenerative cell therapies for sensorineural hearing loss. Comparable as a hearing-loss therapeutics innovator though operating in a different modality (cell therapy vs small molecule).
  • Audion Therapeutics: Audion Therapeutics is a Netherlands-based emerging biotech developing small-molecule therapeutics for hearing loss and inner ear regeneration. Directly comparable in therapeutic area with Phase 1 assets in hearing loss.
  • Strekin AG: Strekin AG is a Swiss clinical-stage biotech focused on otology indications including SSNHL and hearing loss. Emerging peer operating in the same therapeutic space with small-molecule pipeline assets.

Broad incumbents

  • MED-EL Elektromedizinische Geräte GmbH: MED-EL is the global leader in cochlear implant systems and an existing AudioCure investor/partner developing electrode insertion trauma applications for AC102. Broader incumbent in hearing loss treatment with overlapping R&D on drug-device combination approaches.

Market position

Strengths1 record

Weaknesses5 records

Competitive moat3 records

Key highlights7 records

Customer concentration

AudioCure Pharma social profiles

Digital presence

AudioCure Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AudioCure Pharma leadership team

Management profile

Number of profiles

Profiles2 records

AudioCure Pharma funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AudioCure Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AudioCure Pharma

What does AudioCure Pharma do?

AudioCure Pharma develops AC102, a novel betacarboline small-molecule drug candidate formulated as an intratympanic gel, for the treatment of sudden sensorineural hearing loss (SSNHL), acute tinnitus, and electrode insertion trauma during cochlear implantation. The compound acts on multiple pathological processes in the inner ear (outer hair cell protection, inner hair cell repair, synaptic restoration, and anti-inflammation) and is being advanced through multinational Phase 2 clinical trials in Europe.

Is AudioCure Pharma a public or private company?

AudioCure Pharma is a private company. It is classified as venture growth investor backed and is currently operating.

When was AudioCure Pharma founded?

AudioCure Pharma was founded in 2012. It employs 11 to 50 people.

Where is AudioCure Pharma based?

AudioCure Pharma is headquartered in Berlin, Germany, in the Europe region.

How does AudioCure Pharma make money?

One revenue line is on record: pharmaceutical drug development and commercialization.

Who are AudioCure Pharma's main competitors?

Direct peers on record are Otonomy, Sensorion, Frequency Therapeutics, Decibel Therapeutics (Regeneron), Spiral Therapeutics and Pipeline Therapeutics. Emerging players are Rinri Therapeutics, Audion Therapeutics and Strekin AG. MED-EL Elektromedizinische Geräte GmbH is listed as a broad incumbent.

Does AudioCure Pharma have an API?

No public API is recorded for AudioCure Pharma.

What industry is AudioCure Pharma in?

AudioCure Pharma's product category is Hearing Loss Therapeutics (Otorhinolaryngology Pharmaceuticals). Its primary akta.pro industry code is HLAKAMAC, Otology & Neurotology (Ear/Hearing/Balance). Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales